Abstract #2406

Analysis of liver function after molecular targeting therapy of HCC with hepatocyte fraction index obtained from gadoxetic acid-enhanced MRI.

Yudai Syogan¹, Satoshi Kobayashi¹, Yu Ueda², Noboru Taniguchi¹, Naoki Ohno¹, Tosiaki Miyati¹, Toshifumi Gabata³, Takeshi Terashima⁴, Kuniaki Arai⁴, and Tatsuya Yamashita⁴

¹Quantum Medical Technology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ²Philips.Japan, Tokyo, Japan, ³Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ⁴Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

Hepatocyte fraction index (HeFra index) obtained from gadoxetic acid-enhanced MR imaging might be possible surrogate marker of liver function after molecular targeting therapy to advanced HCC, and the molecular targeting therapy to advanced HCC do not affect the function of background liver parenchyma.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.